By Fineline Cube 
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase III BRUIN CLL-322 clinical trial, demonstrating that Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab significantly improved progression-free survival (PFS) compared to venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
Clinical Trial Results
Drug Profile & Development Status
- Molecule: Pirtobrutinib – non-covalent (reversible) Bruton’s tyrosine kinase (BTK) enzyme inhibitor
- Global Commercialization: Eli Lilly (worldwide), Innovent Biologics (mainland China)
- China Approvals:
- October 2024: Monotherapy for relapsed/refractory mantle cell lymphoma (MCL) after ≥2 prior therapies (including BTK inhibitor)
- February 2026: Second-line treatment for CLL/SLL
- Innovation: Reversible binding mechanism may overcome resistance seen with covalent BTK inhibitors
Market Impact & Strategic Implications
- CLL/SLL Market Opportunity: Global CLL market projected to reach $8.5 billion by 2028, with relapsed/refractory segment representing significant unmet need
- Competitive Differentiation: Jaypirca’s efficacy in patients previously treated with covalent BTK inhibitors addresses a critical gap in current treatment paradigms
- Commercial Strategy: Lilly plans to submit regulatory applications to FDA and EMA based on these Phase III results, potentially expanding Jaypirca’s label to include combination therapy
- China Partnership: Innovent Biologics’ commercial infrastructure in mainland China provides established market access for potential combination regimen approval
Analyst Commentary
“The BRUIN CLL-322 results position Jaypirca as a potential backbone therapy in CLL/SLL treatment, particularly given its activity in heavily pre-treated patients,” said Sarah Chen, biotech analyst at Morgan Stanley. “The reversible BTK inhibition mechanism appears to deliver meaningful clinical benefits where covalent inhibitors have failed.”
| Endpoint | Result |
|---|---|
| Primary Endpoint | Progression-free survival (PFS) – met with statistical significance |
| Assessment Method | Independent Review Committee (IRC) |
| Treatment Duration | Up to two years, followed by treatment discontinuation until disease progression |
| Key Finding | Statistically significant and clinically meaningful PFS improvement with Jaypirca combination |
| Subgroup Analysis | Consistent benefits observed regardless of prior covalent BTK inhibitor therapy status |
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial expectations for Jaypirca. Actual results may differ due to risks including regulatory review outcomes, competitive developments, and market adoption rates.-Fineline Info & Tech